San Diego Veteran's Affairs Medical Center, San Diego, CA 92161, USA.
Curr Cardiol Rep. 2013 Jun;15(6):372. doi: 10.1007/s11886-013-0372-4.
Heart failure is a major burden to the health care system in terms of not only cost, but also morbidity and mortality. Appropriate use of biomarkers is critically important to allow rapid identification and optimal risk stratification and management of patients with both acute and chronic heart failure. This review will discuss the biomarkers that have the most diagnostic, prognostic, and therapeutic value in patients with heart failure. We will discuss established biomarkers such as natriuretic peptides as well as emerging biomarkers reflective of myocyte stress, myocyte injury, extracellular matrix injury, and both neurohormonal and cardio-renal physiology.
心力衰竭不仅给医疗系统带来了成本负担，也给发病率和死亡率带来了负担。生物标志物的合理应用对于快速识别和优化急性和慢性心力衰竭患者的风险分层和管理至关重要。这篇综述将讨论在心力衰竭患者中具有最有诊断、预后和治疗价值的生物标志物。我们将讨论已建立的生物标志物，如利钠肽，以及反映心肌应激、心肌损伤、细胞外基质损伤以及神经激素和心肾生理学的新兴生物标志物。
